Register a trial

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT06358157




Registration number
NCT06358157
Ethics application status
Date submitted
29/03/2024
Date registered
10/04/2024

Titles & IDs
Public title
The Ladera Large Bore Closure Feasibility Study
Scientific title
Evaluation of the Safety and Performance of the Ladera Medical Suture-Mediated Large Bore Closure (LBC) System
Secondary ID [1] 0 0
CLN02001
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Vascular Closure 0 0
Femoral Arteriotomy Closure 0 0
Condition category
Condition code

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Devices - Ladera LBC System

Experimental: Ladera LBC System - The Ladera LBC System will be used in all participants enrolled in the study


Treatment: Devices: Ladera LBC System
Use of the Ladera LBC System to close the femoral arteriotomy
Intervention code [1] 0 0
Treatment: Devices
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Primary Safety Endpoint: Major Arterial Access Site Closure-related Complications
Timepoint [1] 0 0
Through 30 days post-procedure
Primary outcome [2] 0 0
Primary Performance Endpoint: Time to Hemostasis
Timepoint [2] 0 0
Post-procedure, usually within 3 hours
Secondary outcome [1] 0 0
Secondary Safety Endpoint: Minor Arterial Access Site Closure-related Complications
Timepoint [1] 0 0
Through 30 days post-procedure
Secondary outcome [2] 0 0
Secondary Performance Endpoint: Time-to-Ambulation
Timepoint [2] 0 0
Post-procedure, usually within 12 hours
Secondary outcome [3] 0 0
Secondary Performance Endpoint: Time-to-Discharge Eligibility
Timepoint [3] 0 0
Post-procedure, usually within 48 hours
Secondary outcome [4] 0 0
Secondary Performance Endpoint: Incidence of Procedural Success
Timepoint [4] 0 0
Through 30 days post-procedure
Secondary outcome [5] 0 0
Secondary Performance Endpoint: Incidence of Device Technical Success
Timepoint [5] 0 0
Post-Procedure, usually within 3 hours

Eligibility
Key inclusion criteria
1. Age 21 or older
2. Scheduled for an elective or planned single percutaneous interventional catheterization procedure involving access through the femoral artery using a unilateral procedural sheath ID within the indicated range or device (OD) if an expandable sheath is used
3. Willing and able to give written informed consent and to complete a follow-up visit at 30 ± 7 days
Minimum age
21 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Baseline

1. Evidence of current systemic bacterial or cutaneous infection, including groin infection
2. Known bleeding disorders including thrombocytopenia (platelet count < 100,000), thrombasthenia, hemophilia or Von Willebrand's disease or known Type II heparin-induced thrombocytopenia
3. Thrombolytics (e.g., streptokinase, urokinase), Angiomax (bivalirudin) or other thrombin-specific anticoagulants planned within 24 hours prior to primary procedure
4. Glycoprotein IIb/IIIa inhibitors planned within 24 hours prior to the primary procedure, during the procedure, or within 48 hours after the primary procedure
5. Planned anticoagulation therapy within 24 hours after the primary procedure such that the activated clotting time (ACT) is expected to be elevated greater than 250 seconds
6. Significant anemia (hemoglobin less than 9 g/dL or hematocrit less than 27%)
7. Significant blood loss requiring transfusion of blood products within 30 days prior to primary procedure
8. Documented left ventricular ejection fraction less than 20%
9. Renal insufficiency (glomerular filtration rate less than 30 ml/min or baseline serum creatinine greater than 2.5 mg/dL) or on renal replacement therapy
10. Significant inflow disease (iliac or artery diameter stenosis greater than 50%) and/or severe peripheral arterial disease (Rutherford Category 5 or 6), as confirmed with pre-primary procedure CT angiography
11. Common femoral artery lumen diameter less than the indicated minimum based on pre-primary procedure CT angiography
12. Evidence of marked tortuosity of the femoral or external iliac arteries in the target leg, based on pre-primary procedure CT angiography
13. Evidence of arterial diameter stenosis (greater than 30%) within 15 mm proximal or distal to arteriotomy site based on pre-primary procedure CT angiography
14. Evidence of anterior wall calcification of the target common femoral artery (other than small, diffuse deposits which in the opinion of the Investigator will not impede the vascular closure procedure) within 15 mm proximal or distal to arteriotomy site based on pre-primary procedure CT angiography
15. Prior target artery closure with any closure device within 90 days prior to the primary procedure, or closure with manual/mechanical compression within 30 days prior to the primary procedure
16. Prior atherectomy, stent, vascular surgery, or vascular graph in the common femoral artery of target leg
17. Known existing nerve damage in the target leg
18. Unsuitable for surgical repair of the target leg access site
19. Connective tissue disease (e.g., Marfan's Syndrome), or significant scarring of the target access site which in opinion of the Investigator, would preclude use of the investigational device in accordance with the IFU
20. Recent (within 60 days) cerebrovascular accident or Q-wave myocardial infarction
21. Morbidly obese or cachectic (BMI greater than 40 kg/m2 or less than 20 kg/m2)
22. Planned major intervention or surgery, including planned endovascular/catheter-based procedure, in the target leg in the 30 days following the primary procedure
23. Ipsilateral or contralateral lower extremity amputation
24. Non-ambulatory (confined to bed or wheelchair)
25. Known allergy to any of the materials used in the LBC System (refer to Instructions for Use)
26. Pregnant, lactating, or planning to become pregnant within 30 days following the primary procedure
27. Would refuse blood transfusion if it were to be needed
28. Current enrollment in another investigational medical device or drug study
29. Previous participation in this study
30. Other medical, social, or psychiatric condition that in the opinion of the Investigator would interfere with participation in the study

Intra-Procedural

1. Access site tissue tract (i.e., estimated distance from skin entry point to arterial anterior surface at arteriotomy) expected to be greater than the indicated maximum
2. Initial common femoral arterial access for the primary procedure achieved with manual palpation or blind arterial stick access, without use of an image guided approach (ultrasound or angiography)
3. During arterial puncture for the primary procedure, the target femoral artery suspected to have experienced a posterior arterial wall needle puncture or need for greater than 2 ipsilateral arterial punctures
4. Primary procedural access site in the profunda femoris or superficial femoral artery or the bifurcation of these vessels
5. Primary procedural access site located at the level or above the inferior epigastric artery and/or above the inguinal ligament based on bony/arterial landmarks (above femoral head on A-P projection)
6. Difficult dilation during initial target femoral artery access (e.g., that damages or kinks dilators) while step-dilating up to the primary procedural sheath
7. Primary procedural access site is in a vascular graft
8. Primary procedural sheath ID greater than the indicated size, or primary procedural device greater than the indicated size if an expandable sheath is used
9. Significant blood loss requiring transfusion of blood products during primary procedure
10. Evidence of overt, actionable bleeding around the primary procedure sheath
11. Primary procedure sheath in place longer than 6 hours
12. Evidence of an acute hematoma (greater than 2 cm in diameter), arteriovenous fistula, pseudoaneurysm, or intraluminal thrombosis at the primary procedure access site
13. Angiographic evidence of laceration, dissection or stenosis in the femoral artery that would preclude use of the investigational device
14. Ipsilateral femoral venous sheath during the primary procedure
15. Activated clotting time (ACT) greater than the target immediately prior to primary sheath removal and planned vascular closure or if ACT measurements are expected to be greater than the target seconds within 24 hours after primary procedure
16. Uncontrolled hypertension (systolic blood pressure greater than the systolic maximum or diastolic blood pressure greater than the diastolic maximum) at the time of primary sheath removal and planned vascular closure
17. Systolic blood pressure less than the systolic minimum at the time of primary procedural sheath removal and planned vascular closure

Study design
Purpose of the study
Treatment
Allocation to intervention
Not applicable
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Not applicable
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
1/10/2024
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
1/04/2025
Actual
Sample size
Target
30
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,VIC
Recruitment hospital [1] 0 0
Macquarie University - Sydney
Recruitment hospital [2] 0 0
Alfred Health - Melbourne
Recruitment hospital [3] 0 0
Monash Health, Victoria Heart Hospital - Melbourne
Recruitment postcode(s) [1] 0 0
- Sydney
Recruitment postcode(s) [2] 0 0
3004 - Melbourne
Recruitment postcode(s) [3] 0 0
3168 - Melbourne

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Ladera Medical
Address
Country
Other collaborator category [1] 0 0
Commercial sector/industry
Name [1] 0 0
Avania
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Ben F Brian, PhD
Address 0 0
Country 0 0
Phone 0 0
6509060874
Fax 0 0
Email 0 0
ben.brian@laderamedical.com
Contact person for scientific queries

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
No/undecided IPD sharing reason/comment


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.


Results not provided in https://clinicaltrials.gov/study/NCT06358157